Patient Selection for Bronchoscopic Lung Volume Reduction by Welling, Jorrit B A et al.
 
 
 University of Groningen
Patient Selection for Bronchoscopic Lung Volume Reduction
Welling, Jorrit B A; Hartman, Jorine E; Augustijn, Sonja W S; Kerstjens, Huib A M;
Vanfleteren, Lowie E G W; Klooster, Karin; Slebos, Dirk-Jan
Published in:
International Journal of Chronic Obstructive Pulmonary Disease
DOI:
10.2147/COPD.S240848
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Welling, J. B. A., Hartman, J. E., Augustijn, S. W. S., Kerstjens, H. A. M., Vanfleteren, L. E. G. W., Klooster,
K., & Slebos, D-J. (2020). Patient Selection for Bronchoscopic Lung Volume Reduction. International
Journal of Chronic Obstructive Pulmonary Disease, 15, 871-881. https://doi.org/10.2147/COPD.S240848
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
OR I G I N A L R E S E A R C H
Patient Selection for Bronchoscopic Lung Volume
Reduction
This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease
Jorrit BA Welling 1,2
Jorine E Hartman 1,2
Sonja WS Augustijn1




1University of Groningen, University
Medical Center Groningen, Department
of Pulmonary Diseases, Groningen, the
Netherlands; 2Groningen Research
Institute for Asthma and COPD,
University of Groningen, University
Medical Center Groningen, Groningen,
the Netherlands; 3COPD Center,
Sahlgrenska University Medical Hospital
and Institute of Medicine, Gothenburg
University, Gothenburg, Sweden
Purpose: Bronchoscopic lung volume reduction (BLVR) is a valuable treatment option for
carefully selected patients with severe COPD. There is limited knowledge about the char-
acteristics and outcomes of patients referred to a specialized center for BLVR. The study
objectives were to investigate the selection rate for BLVR treatment in patients referred for
this treatment and to investigate the differences between patients that were selected for
BLVR and patients that were not.
Patients and Methods: We performed a retrospective analysis of patients with severe
COPD who were referred to our hospital to assess eligibility for BLVR treatment. Our
parameters included demographics, comorbidity, chest computed tomography characteristics,
reasons for rejection from BLVR treatment and patient survival.
Results: In total, 1500 patients were included (mean age 62 years, 50% female and forced
expiratory volume in 1 s 33% of predicted). Out of this group, 282 (19%) patients were selected
for BLVR treatment. The absence of a suitable target lobe for treatment, an unsuitable disease
phenotype and insufficient lung hyperinflation were the most important factors for not being
selected. Patients that were selected for any BLVR option lived significantly longer than the
group of patients that were not selected for BLVR (median 3060 versus 2079 days, P<0.001).
Conclusion: We found that only a small proportion of patients that are referred for BLVR
treatment is eligible for a BLVR treatment, indicating a need for both better referral tools and
for the development of new therapies for this group of patients. Furthermore, our data
suggest that selection for BLVR is associated with a significant survival benefit.
Keywords: bronchoscopic lung volume reduction, patient selection, endobronchial valves,
lung volume reduction coils
Introduction
Bronchoscopic lung volume reduction (BLVR) is a valuable treatment option for
patients with severe COPD and emphysema, aimed at reducing hyperinflation of the
lung.1 BLVR using endobronchial valves (EBV) and lung volume reduction coils
(LVRC) have been studied most extensively and demonstrated to be effective, with
an acceptable safety profile.2
Dedicated patient selection for BLVR is essential in achieving clinically mean-
ingful results after treatment. For example, for the EBV treatment, the absence of
interlobar collateral ventilation is necessary to achieve successful outcomes and for
the LVRC treatment superior outcomes are observed in patients with very severe
static hyperinflation and absence of significant airway disease.3–7
Several questions on patient selection for BLVR remain unanswered. For example,
it is unknown what proportion of patients referred for BLVR is potentially eligible for
Correspondence: Jorrit BA Welling
Department of Pulmonary Diseases,
University Medical Center Groningen,
Groningen, the Netherlands
Email j.b.a.welling@umcg.nl
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com International Journal of Chronic Obstructive Pulmonary Disease 2020:15 871–881 871
http://doi.org/10.2147/COPD.S240848
DovePress © 2020 Welling et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
any form of BLVR treatment and to our knowledge, this
group of patients has not been well characterized in the
literature. Furthermore, the development of new insights in
BLVR treatment during this period led to changes in the
inclusion and exclusion criteria for these treatments which
potentially could influence the proportion of selected
patients.
Therefore, we aimed to investigate 1) which proportion
of patients that were referred to our hospital were actually
selected for BLVR treatment; 2) the differences in character-
istics and survival between patients that were and were not
selected for BLVR; 3) to what extent applying updated
criteria for eligibility would have affected the selection rate.
Patients and Methods
Study Design and Patient Population
We performed a retrospective analysis of the first 1500
patients who were consecutively referred to assess elig-
ibility for BLVR treatment between March 2007 and
October 2014, from 62 different hospitals in the
Netherlands to our hospital. Given the retrospective and
anonymous nature of the analyses, this research did not
fall within the scope of the WMO (Dutch Medical
Research with Human Subjects Law) and therefore review
by a medical ethical committee was not required.
Evaluation of Eligibility
Patient selection for BLVR in our hospital starts with the
referral of a patient by their pulmonary physician. Referring
physicians are requested to include recent lung function
results (spirometry and body plethysmography), chest com-
puted tomography (HRCT) scan, and a complete medical
history in their referrals. During a multidisciplinary team
meeting, a first selection is made. Potential BLVR
candidates are invited to our hospital for a consultation
with an interventional pulmonologist.
Treatment
Patients that were eligible for BLVR treatment were
included in clinical trials investigating EBV,3,8–11
LVRC,12–15 polymeric lung volume reduction,16
pneumostoma17–19 and airway bypass stents20 or in our
regular EBV treatment program (BREATH-NL:
NCT02815683).
Outcomes
The primary outcome of this study was the selection rate for
BLVR treatment. Secondary outcomes were derived from
the referral documentation and included demographics, lung
function (spirometry and body plethysmography), smoking
status, oxygen therapy use and maintenance anticoagulant
use. Furthermore, the medical history of all patients was
screened for a selection of comorbidities. All available
CT scans were visually reviewed and assessed by JBAW
for the presence of specific characteristics, these assessments
were supervised by DJS.
The degree of emphysema destruction was scored on a 0
to 4 qualitative Likert scale with higher scores indicating
more emphysematous destruction (Figure 1).21,22 In case of
ineligibility for BLVR, we reported the reasons why patients
were found not to be eligible for treatment. The survival
status of the referred patients was verified with the Dutch
government (Personal Records Database) on June 16, 2019.
Theoretical Model
We applied some of the most recent inclusion and exclu-
sion criteria for EBV and LVRC, according to the
guidelines,1 on our cohort to assess the proportion of
patients eligible for these treatments and whether this
Figure 1 Qualitative scale of emphysematous destruction, scored on a 0 to 4 scale with higher scores indicating more emphysematous destruction.
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proportion was different from the proportion of patients
actually selected for these treatments. The criteria applied
for EBV treatment included forced expiratory volume in 1
s (FEV1) between 20% and 50% of predicted, residual
volume (RV) ≥175% of predicted, RV/total lung capacity
(TLC) ratio of ≥0.58, visually intact major fissure (left or
right) and emphysema destruction ≥2 on destruction scale
(Figure 1).
The criteria applied for LVRC included FEV1 between
20% and 50% of predicted, RV ≥200% of predicted, RV/
TLC ratio of ≥0.58 and emphysema destruction ≥2 on the
destruction scale (Figure 1).
Statistical Analysis
Differences in patient characteristics between the group
that was selected for treatment and the group that was
not were analyzed using an independent-samples T-test in
case of normal distribution of data and a Mann–Whitney-
U test in case of non-normal distribution. A Chi-squared
test was used in the case of categorical data. Due to the
explorative nature of the CT data, only demographic data
are presented and no statistical analysis was performed.
Survival time was defined as the time after the date of
discussion in the multidisciplinary team meeting until the
date of verification with the Dutch government. Survival
was analyzed using the Kaplan–Meier method.
Comparison in survival between the groups selected or
not selected for treatment was performed using the
Mantel–Cox log-rank test and comparison in survival
between EBV and LVRC treatment was performed using
Breslow’s test. All statistical analyses were performed
using SPSS version 23 (IBM, New York, NY, USA).
P-values <0.05 were considered statistically significant.
Results
In total, 1500 patients (50% female) were included in our
analysis, with a mean age of 62 years and FEV1 of 33
±14% of predicted (additional patient characteristics are
shown in Table 1). From this group, 651 patients (43%)
were invited for a consultation in our hospital. Of the total
referred population 282 (19%) patients were selected for
a clinical trial or regular treatment program and therefore
a total of 1218 (81%) patients were considered not eligible
for BLVR (see Figure 2 for patient flowchart).
Out of the group of 282 patients that were selected for
a bronchoscopic treatment, 175 patients (62%) were
selected for EBV, 93 patients (33%) for LVRC, 3 patients
(0.2%) for airway bypass stents, 9 patients (3%) for
polymeric lung volume reduction and 2 patients (0.1%)
for a pneumostoma.
Patients selected for BLVR were significantly younger
(59 versus 63 years), had a lower FEV1 (28% versus 34%
of predicted) and a higher RV (237% versus 215% of
predicted) compared to the group of patients not selected
for BLVR (all P<0.001).
The most frequently encountered reasons for ineligibil-
ity for BLVR treatment were: absence of a suitable target
lobe for treatment (18%), unsuitable disease phenotype for
treatment (chronic bronchitis, frequent exacerbations,
asthma) (18%) and insufficient hyperinflation of the
lungs (16%). See Table 2 for the complete list of contra-
indications.
The CT scans of 1211 patients (81%) could be
assessed, for 289 patients assessment was not possible
because of scan unavailability or insufficient image quality
for assessment. The proportion of patients with
a homogeneous and heterogeneous distribution of emphy-
sema was similar (52% versus 48%). Upper lobe predo-
minant emphysema was observed more often than lower
lobe predominant emphysema (71% versus 29%). The left
major fissure was found to be visually intact in 44% of
patients, the right major in 25% of patients and the right
minor fissure in 12% of patients (see Table 3).
Table 4 displays the reported comorbidities. Patients
referred for BLVR had an average of 1.4 comorbidities and
the most frequently encountered comorbidities were hyper-
tension (22%), confirmed or suspected asthma (18%) and
coronary artery disease (10%). Patients selected for BLVR
had significantly less comorbidities compared to the group
of patients not selected for BLVR (1.1 versus 1.4, P<0.01).
The survival status of 1272 patients (85%) could be
verified. The overall median survival was 2316 days (95%
CI: 2146–2485 days). The median follow-up was 2351
days (95% CI: 2451–2514 days). Patients that were
referred to our hospital but were not invited for consulta-
tion had a median survival of 1808 days (95% CI:
1622–1994) and patients who were invited for consultation
but who were not selected for treatment had a median
survival of 2524 days (95% CI: 2234–2814). Patients
that were selected for BLVR lived significantly longer
than the group of patients that was not selected for
BLVR (median 3060 versus 2079 days, P<0.001), see
Figure 3. No significant survival difference was observed
between patients who were selected for EBV treatment
and those who were selected for LVRC (P=0.45).
Dovepress Welling et al
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Theoretical Model
When applying some of the currently established inclusion
and exclusion criteria for endobronchial valve treatment
and lung volume reduction treatment, we identified 283
patients eligible for EBV treatment (19%) while 175
patients (12%) were actually selected for EBV in this
cohort and 144 patients (10%) would currently be eligible
for LVRC while 93 patients (6%) were actually selected
for LVRC (Figure 4).
Discussion
Only one out of five patients who were referred for BLVR
treatment to our hospital were selected for BLVR treat-
ment. Ineligibility for BLVR treatment was most often
caused by the absence of a suitable target lobe for treat-
ment, an unsuitable disease phenotype for treatment and
insufficient lung hyperinflation. Overall survival in the
group of patients referred for BLVR was poor with
a median survival of approximately 6 years.
To our knowledge, this is the largest study investigat-
ing patients referred for BLVR eligibility assessment. In
a recent study by Polke et al, who studied patients that
were referred to a BLVR expert center in Heidelberg
(Germany), a higher proportion of patients were found to
be eligible for BLVR treatment, possibly caused by a more
strict preselection of patients for referral.23 The same study
also found the absence of a suitable target lobe to be the
most frequent contra-indication for BLVR, which is in line
with the results of our study.23
Only a small proportion of the already preselected
group of patients that were considered to be eligible for
BLVR by the referring physician is selected for BLVR
treatment. This highlights both the need for improved
referral strategies on the one hand and the important
need for additional therapeutic options for patients with
severe COPD on the other hand. Alternative interventions
for BLVR include lung volume reduction surgery or lung
transplantation; however, both treatments suffer from huge
limitations related to the invasiveness of the procedure,
scarce availability and strict selection procedures. Patients
with a severe chronic bronchitis phenotype of COPD are
a common example of an unsuitable disease phenotype for
BLVR. Both endobronchial treatment with liquid nitrogen
Table 1 Patient Characteristics





Number of patients 1500 282 1218
Age (years) 62±9 59±8 63±9 P<0.001
Female 750 (50%) 179 (63%) 571 (47%) P<0.001
BMI (kg/m2) 24±5 24±4 24±5 P=0.02
Pack-years (years) 38±18 36±16 38±18 P=0.18
FEV1 (L) 0.9±0.5 0.8±0.3 1.0±0.5 P<0.001
FEV1 predicted (%) 33±14 28±8 34±15 P<0.001
FVC (L) 2.8±1.0 2.6±0.9 2.8±1.0 P=0.01
FVC predicted (%) 79±21 77±19 79±22 P=0.08
RV (L) 4.8±1.3 4.9±1.1 4.7±1.3 P=0.03
RV predicted (%) 219±56 237±46 215±58 P<0.001
TLC (L) 7.8±1.6 7.8±1.5 7.8±1.6 P=0.77
TLC predicted (%) 130±18 135±15 129±19 P<0.001
Current smoker 123 (8%) 10 (4%) 113 (9%) P<0.01
Ex-smoker 1051(70%) 263 (94%) 788 (65%) P<0.001
Never smoker 16 (1%) 2 (1%) 14 (1%) P=0.52
Unknown 302 (20%) 6 (2%) 296 (24%) P<0.001
Oxygen therapy 418 (28%) 80 (28%) 338 (28%) P=0.84
Maintenance anticoagulant use 280 (19%) 44 (16%) 236 (19%) P=0.14
Participation in previous pulmonary
rehabilitation or weekly physiotherapy
684 (46%) 174 (62%) 510 (42%) P<0.001
Weekly physiotherapy 567 (38% 168 (60%) 399 (33%) P<0.001
Notes: Data are presented as the number of patients (%), mean ± standard deviation or percentage of the predicted value ± standard deviation. Differences in patient
characteristics between the selected and not selected group for treatment were analyzed using a 2-samples T-test or Chi-square test.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity.
Welling et al Dovepress
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cryospray and targeted lung denervation are currently
under development for this phenotype. Liquid nitrogen
cryospray is a treatment aimed at inducing an airway
tissue healing effect by destroying the hyperplastic goblet
cells and excess submucous glands.24 Target lung denerva-
tion is a treatment designed to decrease airway resistance
and mucus hyper section, by inhibiting parasympathetic
pulmonary nerves, using radiofrequency ablation
therapy.25
New insights into BLVR treatment caused inclusion
and exclusion criteria for these treatments to change over
time, which might have affected the proportion of patients
considered eligible for BVLR. For example, a previous
contra-indication for EBV trials included the presence of
alpha-1 antitrypsin deficiency, but these patients are now
considered eligible for treatment.3,26 When we applied the
most recent inclusion and exclusion criteria on our cohort,
we observed a discrepancy between the number of patients
that were eligible for treatment and those who were actu-
ally selected for treatment. This could be the result of the
fact that not all treatments were available at all times
during the time frame of this study, the clinical trial
context with strict in and exclusion criteria or because
we applied only a selection of the most stringent criteria
in our model.
A significant survival benefit was observed for the
group of patients that was selected for BLVR treatment,
when compared to the group that was not selected for
treatment. This survival benefit was already observed in
several previous studies which demonstrated that when
successful lobar atelectasis is achieved after EBV treat-
ment, patients have a substantial, persisting survival
benefit.27–29 Structural survival data for the LVRC treat-
ment are not yet available. We acknowledge that the sur-
vival benefit observed in the group of patients that were
selected for treatment might have not only been due to
a direct result of the actual intervention but also caused by
the exclusion of patients that were too frail, due to any
cause, for treatment. On the other hand, both the degree of
hyperinflation and airway obstruction were higher in the
group selected for treatment, suggesting the selection of
patients with severe disease for treatment. In addition,
given that most treatments in this cohort took place in
























Figure 2 Study flowchart.
Abbreviation: PLVR, polymeric lung volume reduction.
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the current data might actually underestimate the survival
benefit of these treatments.
Patients selected for BLVR had significantly less comor-
bidities than patients who were not selected for BLVR. On
average, the referred patients had more than one comorbidity.
However, this was still lower than in a study by Putcha et al,
possibly caused by the underreporting of comorbidities by
the referring physicians in our cohort or because of the fact
that the referring physicians already referred a preselected
population due to study selection criteria on comorbidity.30,31
We assessed the CT characteristics of the referred
patients and found the left major fissure to be most often
intact on the CT scans of the referred patients, followed by
the right major fissure and the right minor fissure. The
proportion of visually intact fissures was in line with
Table 2 Contraindications in Patients Not Selected for BLVR
Contraindication Prevalence
Number of patients 1218
Number of contraindications
Mean ± standard deviation 1.3±0.9
Median (range) 1 (0–5)
Absence of suitable target lobe for treatment 221 (18%)
Unsuitable disease phenotype (chronic bronchitis,
frequent exacerbations, asthma)
219 (18%)
Insufficient hyperinflation of the lungs 197 (16%)
Presence of comorbidity 162 (13%)
Homogeneous distribution of emphysema 125 (10%)
Incomplete interlobar fissures 109 (9%)
Patient renounced treatment 95 (8%)
Pulmonary function testing outcomes not meeting
minimum hyperinflation and/or airway obstruction
requirements
95 (8%)
No trial available at moment of evaluation 94 (8%)
Low degree of emphysema destruction 83 (7%)
Did not stop smoking for >6 months 79 (7%)
Did not yet participate in pulmonary rehabilitation 73 (6%)
Maintenance anticoagulant use 54 (5%)
Too high degree of emphysema destruction 53 (4%)
Presence of bullae 47 (4%)
Paraseptal emphysema phenotype 47 (4%)
High level of exercise capacity 43 (4%)
Suspicious nodules in the lung that require follow-up 38 (3%)
Too poor condition for treatment 35 (3%)
Prior thoracic surgery 31 (3%)
Body mass index too high or too low 26 (2%)
Pulmonary Hypertension 22 (2%)
Alpha-1 antitrypsin deficiency 15 (1%)
Lung transplanted before BLVR treatment 3 (0.2%)
Notes: Data are presented as number of contraindications (percentage of patients
with contraindication), mean ± standard deviation, median (range).
Abbreviation: BLVR, bronchoscopic lung volume reduction.
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Giant bullae 195 (16%) 21 (8%) 174 (19%)
Nodules requiring
follow up
89 (7%) 27 (10%) 62 (7%)
Fibrosis 23 (2%) 2 (0.7%) 21 (2%)
Pleural pathology 13 (1%) 2 (0.7%) 11 (1%)
(Continued)
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previously published data on this topic, and also in agree-
ment with the latest clinical trials investigating EBV and
intrabronchial valves, in which the left upper and left
lower lobe were selected for treatment in more than 75%
of cases.11,32,33
This study has several limitations: first of all, our
population is representative of the group of patients
referred to a BLVR center but not of the total population
of patients with severe emphysema, and can therefore
not serve to accurately assess the proportion of eligible
patients for BLVR in the total population of patients
with emphysema. Second, inherent to the retrospective
nature of this study, we had to rely on the quality of the
referral documentation from other hospitals. Incomplete
or incorrect referral documentation might have espe-
cially affected the data presented on comorbidity,
which was based on the medical history included in
the referral documentation, probably leading to an
underestimation of comorbidity.31 Third, the CT scans
were of very different quality and settings, because
referral material was used, making a preferred quantita-
tive assessment not possible.34 These scans were
assessed by one reviewer only (JBAW), under super-
vision of one of the authors (DJS), a task that in an
ideal setting would have been performed by a panel of
reviewers. Fourth, since these were the first 1500 BLVR
referrals sent to our hospital, most patients were treated
in a clinical trial context, which probably led to a more
strict selection compared to treatment outside the clin-
ical trial context, underestimating the number of patients
eligible for BLVR treatment. Fifth, it would have been
of additional value to include a survival prediction index
like BODE, but we did not have the necessary data
available to perform this.35
















median (range) 1 (0–11) 1 (0–6) 1 (0–11)
Hypertension 323 (22%) 72 (26%) 251 (21%)
Confirmed or
suspected asthma
270 (18%) 58 (21%) 212 (17%)
Coronary artery
disease
153 (10%) 16 (6%) 137 (11%)
Dyslipidemia 117 (8%) 20 (7%) 97 (8%)
Diabetes 112 (8%) 15 (5%) 97 (8%)
Osteoporosis 105 (7%) 19 (7%) 86 (7%)
Obesity (BMI>30) 105 (7%) 12 (4%) 93 (8%)
Atrial fibrillation 84 (6%) 4 (1%) 80 (7%)
Myocardial
infarction
82 (6%) 6 (2%) 76 (6%)
Cerebrovascular
incident
76 (5%) 12 (4%) 64 (5%)
Alpha-1 antitrypsin
deficiency
70 (5%) 16 (6%) 54 (4%)
Peripheral artery
disease
59 (4%) 6 (2%) 53 (4%)
Heart failure 54 (4%) 5 (2%) 49 (4%)
Depression 54 (4%) 11 (4%) 43 (4%)
Pulmonary
embolus
48 (3%) 10 (4%) 38 (3%)
Pulmonary
hypertension




43 (3%) 7 (3%) 36 (3%)
Degenerative joint
disease
38 (3%) 4 (1%) 34 (3%)














148 (12%) 25 (9%) 123 (13%)
Notes: Data is presented as number of patients (percentage of patients) or as
percentage of cases. Destruction score based on a 1 to 4 Likert scale, with higher
scores indicating more severe emphysematous destruction.
Abbreviations: CT, computed tomography; LUL, left upper lobe; LLL, left lower
lobe; RUL, right upper lobe; RLL, right lower lobe.
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A strength of our study is the large number of patients
that were included in this retrospective study. Another
strength of our study is the fact that we were able to verify
the survival status of our patients with the Dutch govern-
ment, which increased the reliability of our survival data.
Future research might include the development of
a model that is able to predict the à priori chances of
BLVR eligibility. Such a model could assist both physi-
cians and patients in deciding whether referral to
a BLVR center is indicated. Indeed, the right patient
should be referred for the right treatment, to improve
efficiency and avoid the burden for the patient. Future
research is needed to identify the size of the potential
pool of patients eligible for BLVR treatment as
a previous study by Pietzsch et al suggested that
BLVR currently is only used in a small proportion of
patients with severe emphysema.36
In conclusion, we found that only a small proportion
of patients that are referred for BLVR treatment is
eligible for a BLVR treatment, indicating a need for
the development of new therapies for this group of
patients and better referral tools. Furthermore, our data
suggest that selection for BLVR is associated with
a significant survival benefit.
Abbreviations
BLVR, bronchoscopic lung volume reduction; COPD,
chronic obstructive pulmonary disease; CT, computed
tomography; EBV, endobronchial valves; FEV1, forced
expiratory volume in 1 s; LVRC, lung volume reduc-
tion coil; RV, residual volume; TLC, total lung
capacity.
Data Sharing Statement
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33 (2%) 5 (2%) 28 (2%)
Gastric ulcer 24 (2%) 2 (1%) 22 (2%)
Pulmonary
malignancy
21 (1%) 2 (1%) 19 (2%)
Anemia 20 (1%) 0 (0%) 20 (2%)
Chronic kidney
disease
15 (1%) 0 (0%) 15 (1%)
Pulmonary fibrosis 10 (0.7%) 0 (0%) 10 (0.8%)
Liver cirrhosis 2 (0.1%) 1 (0.4%) 1 (0.1%)
Notes: Data are presented as the number of patients (percentage of patients),
mean ± standard deviation or median (range). Differences in the number of
comorbidities were assessed using Mann–Whitney U-test. *P<0.01.
Abbreviation: BMI, body mass index.














Selected 991 256 170 42 3
Not selected 281 748 377 62 2
Log-rank  (Mantel-Cox): P<0.001
Hazard ratio: 1.65 (95% CI: 1.39 -1.97)
Selected for BLVR
Not selected for BLVR



































EBV 175 157 100 25 2
LVRC 92 87 64 20 1
Invited 637 459 223 38 3
Not Invited 368 302 162 25 1
Difference between EBV and LVRC: P=0.45 (Breslow)

















Figure 3 Kaplan-Meier plots of survival. (A) Survival of the patients that were selected for treatment and the patients that were not selected for treatment. (B) Survival of
the patients that were selected for EBV, selected for LVRC, invited to our hospital for consultation but not selected for BLVR, not selected for BLVR and not invited to our
hospital for consultation.
Abbreviations: EBV, endobronchial valve treatment; LVRC, lung volume reduction coil treatment; BLVR, bronchoscopic lung volume reduction; MDT, multidisciplinary
team meeting.
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≥20%predicted  & ≤50%predicted
N=1161 (77%)
RV ≥175%predicted & RV/TLC ≥0.58 
N= 545 (36%)





Actually selected for EBV in cohort: 175 (12%)




≥20%predicted  & ≤50%predicted
N=1161 (77%)
RV ≥200%predicted & RV/TLC ≥0.58 
N= 469 (31%)
Destruction LUL and RUL ≥2 
OR LLL and RLL ≥2 
N=144 (10%)
Lung Volume Reduction Coils
Actually selected for LVRC in cohort: 93 (6%)
A
B
Figure 4 Eligibility for EBV and LVRC after application of current inclusion and exclusion criteria. (A) Eligible patients for EBV treatment. (B) Eligible patients for LVRC
treatment.
Abbreviations: N, number of patients; FEV1, forced expiratory volume in 1 s; RV, residual volume; TLC, total lung capacity; EBV, endobronchial valve treatment; LUL, left
upper lobe; RUL, right upper lobe; LLL, left lower lobe; RLL, right lower lobe; LVRC, lung volume reduction coil treatment.
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